58 results about "Amlodipine" patented technology

The invention discloses a preparation method of perindopril amlodipine tablets, and belongs to the field of pharmacy. The perindopril amlodipine tablet is prepared from the following raw material medicines: arginine perindopril and amlodipine besylate and auxiliary materials: lactose, microcrystalline cellulose, hydrophobic colloidal silicon dioxide and magnesium stearate. The preparation method of the perindopril amlodipine tablet comprises the following steps: weighing according to the prescription amount, crushing and sieving the raw materials for pretreatment, sieving the whole particles of the auxiliary materials for pretreatment, premixing, feeding and total mixing, tabletting and the like. The prepared perindopril amlodipine tablet is relatively good in quality, high in stability and relatively few in waste products.

The invention relates to an application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and medicinal preparations. The invention provides application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV (human papillomavirus) infection. The dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. According to the scheme, the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV is reported for the first time, and an in-vitro cell experiment is carried out through azelnidipine in the dihydropyridine compound; furthermore, the inhibition effect on the HPV virus is verified through mouse intradermal vaccination virus model drug delivery and mouse vaginal vaccination virus model drug delivery.

Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

The invention provides a quick-release composition, the quick-release composition contains sacubitril valsartan or a salt thereof and amlodipine or a salt thereof, and the two active components in the quick-release composition can realize quick release. The invention also relates to application of sacubitril valsartan or salt thereof, amlodipine or salt thereof and a quick-release composition thereof in preparation of medicaments for treating cardiovascular diseases.

The invention belongs to the field of medicines, and relates to a perindopril amlodipine solid preparation as well as a preparation method and application thereof. In the prior art, when an in-vitro dissolution behavior of an imitated medicine of perindopril and amlodipine tablets is investigated, it is found that the release behaviors of the perindopril and amlodipine tablets are difficult to keep consistent with those of an original developed preparation at the same time, so that the safety and effectiveness of the imitated medicine are not guaranteed. A large number of experiments find that the particle size distribution and the water content of the microcrystalline cellulose are controlled, so that the in-vitro dissolution curve of the perindopril amlodipine solid preparation is similar to that of an imported original development agent produced by an original research company, the possibility of bioequivalence with the original development agent is improved, and the drug consistency evaluation requirement is met.

Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

The present invention provides a composition of nebivolol and amlodipine, comprising nebivolol, amlodipine and a pharmaceutical excipient. The nebivolol comprises one or more of nebivolol, a pharmaceutically acceptable salt thereof, and a solvate thereof. The amlodipine comprises one or more of amlodipine, a pharmaceutically acceptable salt thereof, and a solvate thereof. The pharmaceutical excipient is selected from one or more of a filler, a binder, a disintegrant, a lubricant, and a glidant. The composition does not contain a colorant and a film coating. The compound preparation of the present invention has good stability, and is beneficial to improving the antihypertensive efficacy, enhancing safety and tolerability, and reducing side effects. Compared to monotherapy, the present invention reduces the number of administered medications and improves the compliance of patients, is beneficial to improving the medication compliance of the elderly patients and individuals with dysphagia, maintains a stable plasma drug concentration, maintains long-term stable blood pressure in hypertensive patients, prevents the patients from discontinuing medication arbitrarily, and prevents disease recurrence and the progression of severe complications.

The present application provides a new application of a pharmaceutical composition containing an ARNi complex, and the new application is an application of the pharmaceutical composition containing the ARNi complex in the preparation of a medicine for treating a hypertension patient who is poorly controlled by amlodipine monotherapy.

The invention relates to a coated compound tablet, in particular to a quick-release composition, which comprises a first active layer, a second active layer and a coating layer, the first active layer comprises sacubitril valsartan or a salt thereof and a pharmaceutically acceptable additive, the second active layer comprises amlodipine or a salt thereof and a pharmaceutically acceptable additive, and the coating layer is coated on the first active layer. The coating layer contains a coating material that is mainly composed of a cellulose derivative, a polyvinyl alcohol, and an aqueous acrylic resin, and the immediate release composition is capable of achieving a desired elution.

The present invention relates to a method for producing (S)-amlodipine succinate comprising reacting (S)-amlodipine (D)-hemitartrate or a solvate thereof with a first base in the presence of a two-phase solvent system comprising a first non-polar organic solvent and water to produce (S)-amlodipine base, removing the water layer, and reacting (S)-amlodipine base with succinic acid to produce (S)-amlodipine succinate. The present invention also relates to a formulation comprising (S)-amlodipine succinate.

The utility model discloses a levamlodipine besylate tablet crusher, and particularly relates to the technical field of tablet processing, the levamlodipine besylate tablet crusher comprises a crushing cavity, the top of the crushing cavity is provided with a sealing cover in a threaded manner, the bottom of the crushing cavity is provided with a charging box in a threaded manner, the sealing cover is fixedly provided with a crushing motor, and the output end of the crushing motor is fixedly provided with a rotating shaft; a first smashing cutter and a second smashing cutter are arranged at the bottom of the rotating shaft, the second smashing cutter is located at the bottom of the first smashing cutter, a dust absorption structure is arranged on the surface of the sealing cover and located on one side of the smashing motor, the dust absorption structure comprises a treatment box, and the treatment box is located on one side of the smashing cavity. According to the levamlodipine besylate tablet crushing device, levamlodipine besylate tablets can be well crushed, generated dust can be absorbed and filtered in the crushing process, the situation that dust escapes in the environment and affects operators is avoided, and the whole levamlodipine besylate tablet crushing device is convenient to disassemble, assemble and maintain.

The invention relates to the technical field of medicine detection, in particular to a method for detecting N-nitroso amlodipine impurities in perindopril amlodipine tablets, which comprises the following steps: S1, preparing a test solution; s2, preparing a reference substance solution; the conditions of high performance liquid chromatography are as follows: Phenomenex Kinetex 2.6 [mu] m C18 100A is taken as a chromatographic column, a Phenomenex guard column is taken as a pre-column, an aqueous solution containing 0.1% (v / v) formic acid and 2mM ammonium acetate is taken as a mobile phase A, acetonitrile containing 0.1% (v / v) formic acid is taken as a mobile phase B, and the column temperature is 45 DEG C; and S4, performing chromatographic analysis. According to the present invention, the N-nitroso amlodipine impurity in the perindopril amlodipine tablet is determined through the high performance liquid chromatography, and the method has advantages of good specificity, good system applicability and good repeatability.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from amlodipine, empagliflozin, folic acid substances and a pharmaceutically acceptable carrier, wherein the amlodipine, the empagliflozin and the folic acid substances are in medicinal effective dose. The invention also provides application of the pharmaceutical composition in preparation of medicines for treating lower limb artery occlusion diseases.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a levoamlodipine folic acid compound tablet and a preparation process thereof, and the preparation process comprises the following steps: mixing microcrystalline cellulose with vitamin C, and enabling nitrite in the microcrystalline cellulose to be in full contact with the vitamin C to obtain a first mixture; mixing folic acid with part of the first mixture to obtain a second mixture; mixing levamlodipine besylate with the remaining first mixture to obtain a third mixture; and uniformly mixing the second mixture, the third mixture and other auxiliary materials, and tabletting to obtain the tablet. The method comprises the following steps: reacting microcrystalline cellulose with vitamin C to consume nitrite in the microcrystalline cellulose so as to prevent the nitrite from reacting with secondary amino in levamlodipine to generate nitrosamine impurities with genetic toxicity;

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to bisoprolol amlodipine tablets and a preparation method thereof. The bisoprolol amlodipine tablet is composed of a bisoprolol fumarate solid dispersion, amlodipine besylate / levamlodipine besylate, a filler, a disintegrating agent and a lubricant, the bisoprolol fumarate solid dispersion takes HPMCP as a carrier material, and triethyl citrate is added. The obtained bisoprolol and amlodipine tablet blocks the contact opportunity of bisoprolol fumarate and amlodipine, the problem of compatibility of bisoprolol fumarate and amlodipine is fundamentally solved, the storage requirement can be met without special packaging, the preparation process is simple, and the industrialization requirement is met.

A pharmaceutical composition comprising azilsartan medoxomil potassium and a calcium channel blocker, a method for preparing same, and use thereof are provided. Azilsartan medoxomil potassium and the calcium channel blocker are formulated into a compound formulation, thus improving the blood pressure lowering efficacy, improving safety and tolerability, and reducing adverse effects. Azilsartan medoxomil potassium can ameliorate peripheral edema caused by amlodipine by means of expanding peripheral venous vessels, while amlodipine can ameliorate adverse effects such as vasogenic edema, dry cough, and the like caused by azilsartan medoxomil potassium.

The application relates to application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and pharmaceutical preparations. The application provides application of the dihydropyridine compound or the salt thereof in preparation of the medicine for preventing and / or treating HPV infection, wherein the dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. The application scheme first reports the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV, and in-vitro cell experiments are carried out through azelnidipine in the dihydropyridine compound, and further, the inhibiting effect of the dihydropyridine compound on HPV virus is verified through medicine administration of a mouse intradermal virus inoculation model and medicine administration of a mouse vaginal virus inoculation model.

A quick-release composition. The quick-release composition comprises sacubitril valsartan or a salt thereof and amlodipine or a salt thereof, wherein both active ingredients in the quick-release composition can realize quick release. The present invention also relates to the use of sacubitril valsartan or a salt thereof and amlodipine or a salt thereof and the quick-release composition thereof in the preparation of a drug for treating cardiovascular diseases.

This invention discloses an extracellular vesicle derived from Gastrodia elata, its preparation method, and its use in preparing drugs for treating glaucoma, belonging to the field of biomedical technology. This invention claims protection for an extracellular vesicle prepared from dried Gastrodia elata. The extracellular vesicles provided by this invention have no significant cytotoxicity and good biocompatibility. Studies have shown that these extracellular vesicles can significantly inhibit apoptosis of R28 cells and loss of Brn3a⁺ cells in the mouse retina in a glutamate excitotoxicity model. In a glaucoma model, these extracellular vesicles can effectively protect the survival of retinal ganglion cells (RGCs) and retinal function, and can significantly reduce retinal neuroinflammatory responses in the glaucoma model. Therefore, the extracellular vesicles provided by this invention have a clear anti-glaucoma-related retinal damage effect and possess great potential for development into drugs for treating glaucoma.

The present invention relates to a pharmaceutical composite formulation containing candesartan, amlodipine, and indapamide as active ingredients for preventing or treating hypertension. By including candesartan, amlodipine, and indapamide at low doses, the pharmaceutical composite formulation according to the present invention can reduce side effects that may occur due to excessive blood pressure reduction, and can be utilized as a composite formulation for preventing or treating hypertension owing to sufficient tolerability and excellent blood pressure-lowering effects.

The present invention provides a pharmaceutical composition containing azilsartan medoxomil potassium and a calcium channel blocker, as well as a method for preparing and using the same. The development of a combination formulation using azilsartan medoxomil potassium and a calcium channel blocker is advantageous in terms of improving antihypertensive effects, improving safety and tolerability, and reducing side effects. Azilsartan medoxomil potassium can alleviate amlodipine-induced peripheral edema by dilating peripheral venous blood vessels, while amlodipine can alleviate adverse reactions such as angioedema and dry cough caused by azilsartan medoxomil potassium. Compared with single drugs, the advantages of combination drugs include: (1) reducing medication dosage and improving patient compliance; (2) improving compliance for elderly people and those with dysphagia; and (3) preventing frequent fluctuations in blood drug concentrations, maintaining stable blood drug concentrations, stabilizing blood pressure in hypertensive patients over the long term, and reducing the side effects of each drug. (4) Avoid patients discontinuing medication on their own, and prevent disease recurrence and progression of malignant complications.

The application relates to application of aminolevulinic acid and rhizomaleae in preparation of preparations for preventing and / or treating radiation-induced lung injury, and belongs to the technical field of medicines. The application provides application of aminolevulinic acid and rhizomaleae in preparation of medicines for preventing and / or treating radiation-induced lung injury. The aminolevulinic acid and the rhizomaleae are combined to prevent and / or treat radiation-induced lung injury caused by ionizing radiation, and under the premise of significantly reducing the administration dose of the aminolevulinic acid and the rhizomaleae, the survival rate of a radiation-induced lung injury model mouse is increased by more than 50%, and the application has the characteristics of small drug dosage, excellent prevention and / or treatment effect, no toxic side effect and no dose dependence.

Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

An orally disintegrating tablet of amlodipine for oral administration comprising: a) amlodipine or pharmaceutically acceptable salts thereof, is present in an amount ranging from 2 to 10% w / w; b) at least one diluent; c) at least one disintegrant is present in the range from 1 to 10% w / w; d) at least one lubricant is present in the range from 0.2 to 7% w / w; e) at least one non-nutritive sweetener is present in the range from 0.1 to 7% w / w; f) at least one or more pharmaceutically acceptable excipients; wherein the ratio of combination of diluents to disintegrant is in the range from 15:1 to 40:1; and wherein orally disintegrating tablet is stable for at least three months under storage conditions of 25°C / 60% RH and 40°C / 75% RH.

This invention relates to a bisoprolol amlodipine tablet and its preparation method, belonging to the field of pharmaceutical formulation technology. The bisoprolol amlodipine tablet of this invention comprises bisoprolol fumarate, amlodipine besylate, chitosan, guanidinoacetic acid, maltodextrin, and pharmaceutically acceptable excipients. This invention utilizes the synergistic effect of chitosan, guanidinoacetic acid, and maltodextrin to form a stable physical barrier layer between the two active ingredients, effectively inhibiting the formation of the addition impurity AML-2, significantly improving the stability of the formulation, and the process is simple and suitable for industrial production.

The invention provides a nebivolol and amlodipine composition. The nebivolol and amlodipine composition is prepared from nebivolol, amlodipine and medicine auxiliary materials, the nebivolol comprises one or more of nebivolol, a pharmaceutically acceptable salt of nebivolol and a solvate of nebivolol; the amlodipine comprises one or more of amlodipine, pharmaceutically acceptable salts and solvates of amlodipine; the medicine auxiliary material is selected from one or more of a filling agent, an adhesive, a disintegrating agent, a lubricating agent and a flow aid; the composition is free of colorants and coating films. The compound preparation disclosed by the invention is good in stability, and beneficial to improving the antihypertensive effect, improving the safety tolerance and reducing the side effect. Compared with a single medicine, the medicine taking quantity is reduced, and the compliance of a patient is improved; for old people or people with dysphagia, the medicine taking compliance can be improved; the blood pressure of a hypertensive patient is maintained to be stable for a long time, the patient is prevented from randomly interrupting medication, and disease recurrence and malignant complication development are prevented.

This invention belongs to the field of compound synthesis technology, specifically relating to a diarylguanidine derivative with anti-lymphoma function, its preparation method, and its application. The chemical name of this diarylguanidine derivative is 3-ethyl-5-methyl-(E)-4-(2-chlorophenyl)-6-methyl-2-((2-(2-(3-phenoxyphenyl)-3-phenylguanidinyl)ethoxy)methyl)-1,4-dihydropyridine-3,5-dicarboxylic acid ester. The preparation method includes step 1: reacting phenol and 4-bromonitrobenzene in DMF solution to obtain 4-nitrodiphenyl ether compounds; step 2: placing the 4-nitrodiphenyl ether compounds in an iron-containing ethanol solution to obtain 4-aminodiphenyl ether compounds; step 3: placing the 4-aminodiphenyl ether compounds and phenyl thioisocyanate in tetrahydrofuran solution to react and obtain 1-(4-phenoxyphenyl)-3-phenylurea compounds; and step 4: reacting the 1-(4-phenoxyphenyl)-3-phenylurea compounds with amlodipine under light irradiation to obtain the target compound. The product of this invention is intended for use in the preparation of anti-lymphoma drugs.

The present disclosure provides a novel lyophilized amlodipine composition that forms an oral solution almost immediately upon mixing with an aqueous diluent when in use. The disclosed lyophilized amlodipine compositions can be stable at room temperature for at least 12-24 months and do not require refrigeration during its transportation, storage, use and its shelf life. Furthermore, the disclosed lyophilized amlodipine compositions are free of any alcohol and / or sodium benzoate that is detrimental to young children (e.g., children less than 6 years old, including infants and neonates) and other vulnerable patient populations. In addition, an oral solution redissolved by the disclosed freeze-dried amlodipine composition does not have the risk of potential dose non-uniformity caused by amlodipine suspension drug sedimentation.

The invention discloses a pharmaceutical composition for treating cardiovascular diseases as well as a preparation method and application thereof, and the composition comprises perindopril or pharmaceutically acceptable salt thereof, amlodipine or pharmaceutically acceptable salt thereof and amino-modified silicon dioxide, the amino modified silicon dioxide is prepared by modifying the surface of silicon dioxide by using 3-aminopropyltriethoxysilane as a coupling agent. The composition provided by the invention can keep stable storage under the condition of not adding an antioxidant, especially can avoid or reduce impurities generated by oxidative degradation of perindopril and amlodipine, and improves the safety of the medicine.

A biodegradable bio-scaffold patch for topical application, consisting of a porous chitosan alginate layer and a poly(lactic acid) carrier layer, wherein the porous layer encapsulates an active ingredient selected from amlodipine, nifedipine or prazosin, and the patch is configured to allow controlled release onto the skin over varicose veins.